

The Role of Obesity in the Development of Left Ventricular Hypertrophy Among Children and Adolescents

Tammy M. Brady¹

Published online: 23 December 2015
© Springer Science+Business Media New York 2015

Abstract Both obesity and hypertension have increased substantially among children over the last several decades. At the same time, mounting evidence has pointed to the role of these and other cardiovascular disease risk factors on the development of end organ damage such as left ventricular hypertrophy in children. While traditionally thought to occur in response to an increased afterload as in systemic hypertension, evidence demonstrates that obesity is associated with left ventricular hypertrophy independent of blood pressure. Both hemodynamic and non-hemodynamic factors contribute to the pathogenesis of obesity-related left ventricular remodeling. However, more contemporary research suggests that adiposity and blood pressure have a greater effect on left ventricular geometry when present together than when present alone. Normalization of left ventricular mass in obese hypertensive individuals requires achievement of both normotension and weight loss. Additional strategies are needed to promote the cardiovascular health of children, with greater emphasis placed on obesity prevention.

Keywords Pediatrics · Blood pressure · Overweight · Youth · End organ damage · Cardiovascular disease

Abbreviations

BMI	Body mass index
BP	Blood pressure
CV	Cardiovascular
CVD	Cardiovascular disease
LV	Left ventricular
LVH	Left ventricular hypertrophy
LVM	Left ventricular mass
LVMI	Left ventricular mass index
RWT	Relative wall thickness
SD	Standard deviation

Introduction

Currently, there are more than 24 million overweight or obese children and adolescents in the USA [1]. Pediatric hypertension, reported to affect only 0.3–1.2 % of children in the 1970s and 1980s [2, 3], is now thought to be present in up to 5 % of all children [4, 5]. This secular increase has been attributed to the concurrent obesity epidemic. When considering that the prevalence of hypertension among overweight and obese children is more than four times that of all children [6], this hypothesis seems plausible.

The association between increased body weight and blood pressure (BP) is well established with many studies demonstrating the increased risk of sustained BP elevations among obese youth. It is becoming more widely recognized that, in addition to this increased risk of hypertension, obese youth are at overall greater cardiovascular disease (CVD) risk. Recent meta-analysis data shows obese children to have higher lipid levels, fasting glucose values, greater homeostasis model assessments of insulin resistance, and higher fasting insulin values than children and adolescents of normal weight [7]. Obese children also have greater carotid intima media

This article is part of the Topical Collection on *Pediatric Hypertension*

✉ Tammy M. Brady
tbrady8@jhmi.edu

¹ Division of Pediatric Nephrology, Johns Hopkins University School of Medicine, 200 North Wolfe Street, #3062, Baltimore, MD 21287, USA

thickness, an ultrasound measurement associated with vascular disease, when compared to normal weight children. Indeed, autopsy studies support this finding. Atherosclerosis can be found among children as young as 2 years of age and is associated with known CVD risk factors such as body mass index (BMI), dyslipidemia, and systolic and diastolic BP [8].

In addition to being associated with atherosclerosis, these CVD risk factors are also associated with another form of end organ damage—left ventricular hypertrophy (LVH). LVH, a pathological remodeling of the heart, has been historically thought to occur primarily in response to an increased afterload as can be seen with systemic hypertension. Mounting evidence, however, points to a significant and independent role of adiposity on the development of LVH among children and adolescents [7]. While the mainstay of therapy of hypertensive children continues to be therapeutic lifestyle change, current guidelines emphasize the need for pharmacological therapy once LVH is present. Contemporary research suggests that a greater emphasis on weight loss may be needed to effectively treat those children with obesity, hypertension, and LVH.

How Is Left Ventricular Hypertrophy Defined?

LVH is defined as an increase in left ventricular mass (LVM). LVM can be calculated using left ventricular (LV) wall thickness and LV cavity size measurements obtained during diastole from 2D M-mode echocardiography:

$$\text{LVM} = 0.81 * [1.04 * (\text{intraventricular septal thickness} + \text{posterior wall thickness} + \text{LV end diastolic internal dimension})^3 - (\text{LV end diastolic internal dimension})^3] + 0.6 \text{ g} [9]$$

Due to the known relationship of body size with LVM, the calculated LVM is then indexed to correct for these differences. There are a multitude of proposed indexing methods available, but the most commonly used method in pediatrics, and the one recommended by the National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents [10•], is $\text{LVM}(\text{g})/(\text{height in meters})^{2.7}$. This indexing by allometric height is thought to best correct for the differences in body size while not “normalizing” LVM when increased fat mass is present. As body size changes dramatically throughout childhood, normal LVM changes as well. To determine if a measurement is elevated in the pediatric population, the indexed value of LVM is compared to normative data. LVH is diagnosed when the LVM index ($\text{LVMI g/m}^{2.7}$) is ≥ 95 th percentile [11•].

Among individuals with LVH, there are two different forms of LV cardiac geometry: concentric hypertrophy, where the LVMI is elevated and the relative wall thickness is elevated ($\text{RWT} = [(2 \times \text{posterior wall thickness in diastole})/\text{LV internal dimension in diastole}]$; elevated is ≥ 0.41), and eccentric hypertrophy where the LVMI is elevated but the relative wall thickness (RWT) is normal (< 0.41) [12]. Among those with a

normal LVMI, some individuals will have an elevated RWT. This category, referred to as concentric remodeling, is also associated with elevated CVD risk [13].

LVH—Why Do We Care?

LVH is a form of end organ damage seen in hypertensive individuals. In children, as with other intermediate CVD outcomes, this form of abnormal cardiac geometry is usually asymptomatic. However, in adults, LVH is associated with ventricular arrhythmias and heart failure and confers a four-time increased risk of CVD morbidity and mortality [14]. These hard outcomes are fortunately not seen frequently in children, but prospective longitudinal studies have demonstrated that CVD risk factors present in childhood persist, or “track,” into adulthood, leading to greater risk of CV events over time [15, 16, 17•]. As described above, the diagnosis of LVH in hypertensive children escalates the prescribed therapeutic interventions to ensure LVM regression and normalization of cardiac structure.

Association of Obesity and LVH Among Children

All children with incident and prevalent hypertension should undergo echocardiography to assess for the presence of LVH and to follow the effectiveness of prescribed therapy which would be demonstrated by LVH regression [10•, 17•]. LVH is present among 34–41 % of hypertensive children at initial diagnosis of hypertension [18–20], can be present among children with presumably good BP control, and has been described in those without hypertension [21, 22]. These findings suggest that CVD risk factors other than BP may have an important role in the development of LVH in children.

We have previously shown that, among hypertensive children, degree of BP elevation is not associated with the presence of LVH. Instead, adiposity as measured by the BMI z score is strongly and independently associated with LVH [23, 24]. Other authors have shown that this association remains true among non-hypertensive children [25]. In a compelling retrospective chart review of healthy, normotensive children 2–19 years of age who underwent echocardiography in one of two time periods [26], the children evaluated in 2008 had significantly higher mean BMI and LVMI than those evaluated in the late 1980s, which was prior to the sudden rise in obesity seen in the USA. In fact, the prevalence of obesity increased fourfold between the eras while the prevalence of LVH doubled. Importantly, their analyses found the determinants of LVMI in both eras to be age, sex, race, and BMI z score.

This association between obesity and LVMI is not a new concept. In 1991, results from the Framingham Heart Study demonstrated that even after adjusting for age and BP, BMI was a strong independent predictor of LVM and LVH in adults

[27]. Since then, both cross-sectional and prospective studies have shown this independent association in children and adults alike. Recently, Dusan et al. showed that LVH and diastolic dysfunction are present in obese normotensive children [28]. In fact, in this study the obese hypertensive children had the same LVMI as the obese normotensive children despite having significantly different blood pressures. Newer evidence has also shown this association to track from childhood to adulthood and to strengthen over time [29, 30], supporting the notion that the antecedents of adult CVD are in childhood. In a longitudinal study of adolescents followed into young adulthood, BMI in both adolescence and adulthood was associated with current and future LVMI. Additionally, the greater the degree of weight gain from adolescence to young adulthood, the greater the increase in LVMI over time, regardless of starting weight [29]. Blood pressure was not independently associated with LVMI in this study.

Mechanisms Contributing to Obesity-Related Cardiac Structure and Function

There are multiple physiologic pathways hypothesized to link increased body mass with increased LVM. These pathways can be categorized, as suggested by Abel et al., into hemodynamic factors and non-hemodynamic factors (further categorized as metabolic factors and direct/other factors) [31••].

Hemodynamic Factors

It necessarily follows that with obesity there is an increase in adipose tissue. This results in greater metabolic requirements, vascularity, circulating blood volume, and cardiac output. Obesity can therefore be considered a mildly volume overloaded state [31••, 32]. Further exacerbating this increase in intravascular volume is the greater levels of sodium intake that accompanies increased caloric intake. With increased intravascular volume, stroke volume increases as does pre-load, resulting in a left shift of the Frank–Starling curve [33]. When these CV alterations are sustained, cardiac remodeling results. This remodeling is at first adaptive and protective but over time becomes maladaptive and detrimental.

It is not just the characteristic increase in adipose mass seen with obesity that leads to the hemodynamic changes resulting in altered cardiac geometry. Metabolic dysfunction plays a prominent role in the pathogenesis of obesity-related LV remodeling. With increasing degrees of obesity and greater demands for fuel storage, adipocytes hypertrophy. Over time, classically activated macrophages and T-lymphocytes infiltrate the expanding adipose tissue leading to the secretion of a multitude of pro-inflammatory cytokines and loss of metabolic control. This phenotypic change from a metabolically

normal state with acceptable vascular function to a metabolically abnormal state characterized by inflammation, adipocyte necrosis, and loss of vascular function contributes to end organ damage [34••].

Hemodynamic changes are also evident with obstructive sleep apnea. This form of sleep disordered breathing is highly prevalent among obese individuals and causes sympathetic nervous system activation and catecholamine release. This neurohumoral response leads to cardiac hypertrophy via direct cardiac effects and indirect effects related to the resultant increase in BP and cardiac contractility [31••].

Chronic hypoxemia and the significant alterations in intrathoracic pressure that typify obstructive sleep apnea present additional mechanisms by which LVH develops. Obstructive sleep apnea has long been recognized as an important cause of resistant hypertension, with successful treatment leading to a decrease in BP of up to 10 mmHg [35]. There is also evidence that adherence to nightly CPAP for a period as short as 6 months can result in a reduction of LV wall thickness [36]. It should also be mentioned that the renin–angiotensin–aldosterone system is also activated with obesity, similarly leading to vasoconstriction, increased BP, and ultimately increased LV mass.

Metabolic Factors

The most commonly understood role of the adipocyte is that of fat and fuel storage.

With progressive obesity, the ability of the adipocytes to store superfluous fuel becomes overwhelmed due to an impairment of adipogenesis. As a result, excess triglycerides are stored in ectopic tissue such as the pancreas, the liver, and the heart. When these organs are exposed to excessive free fatty acids, lipid droplets accumulate in the cytosol proximal to mitochondria. Organ dysfunction and occasional failure result, leading to the clinical comorbidities of diabetes mellitus, non-alcoholic steatohepatitis, and dilated cardiomyopathy [37••].

Insulin resistance and hyperinsulinemia, sequelae from beta-cell failure due to lipotoxicity, promotes LVH via several interconnected mechanisms. Glucotoxicity can directly and indirectly affect the cardiomyocyte. Abnormal insulin regulation increases hepatic angiotensin synthesis; angiotensin II, a cardiomyocyte growth factor, increases as a result, leading to myocardial hypertrophy, fibrosis, and apoptosis. Hyperinsulinemia also activates the sympathetic nervous system further leading to myocardial dysfunction. There may also be a role of advanced glycation end products in the heart; however, this is controversial.

When visceral fat deposition involves the heart, there is an increased amount of epicardial fat present. The amount of epicardial fat is correlated with the severity of LVH [38]. Just as described above, this adipose tissue is dysfunctional and the

cardiomyocytes hypertrophy as a consequence of excessive free fatty acid accumulation and lipotoxicity. Inflammation, adipokine secretion, and vessel expansion then follow. Further, the invasion of fat tissue impairs cardiac contractility and limits the dilatory capacity of the left ventricle [38].

Beyond its role as a site for fat depot, the adipocyte is an active endocrinological cell. It secretes multiple pro-inflammatory cytokines which have a role in cardiac remodeling. These adipokines can directly influence hypertrophy, apoptosis, fibrosis, and contractility.

Direct and Other Factors

Adipokines are cytokines, hormones, and inflammatory markers produced by adipose tissue. They are upregulated in obesity and have direct and indirect roles in the development of LVH. Adipokines contribute to myocyte extracellular matrix regulation and apoptosis, two major aspects of cardiac remodeling. Two adipokines deserve mention for their role in cardiac remodeling. Adiponectin, an adipokine almost exclusively synthesized by the adipocyte, has an important role in the regulation of lipid and glucose metabolism. In the obese state, adiponectin activity is diminished due to both decreased adiponectin secretion and decreased receptor expression. Diminished adiponectin activity not only contributes to LVH via the insulin resistance that results but also leads to cardiac disease via the loss of its usual protective effects of decreasing inflammation, preventing endothelial cell adhesion and diminishing foam cell accumulation in the heart [31•, 34•, 39].

Another adipokine with a significant role in obesity is leptin. Leptin regulates feeding behavior and body weight. Interestingly, obese individuals have elevated leptin but remain resistant to its “obesity-preventative” properties [40]. As such, leptin resistance is thought to play a prominent role in obesity. As this pertains to the heart, hyperleptinemia leads to unfavorable cardiac sequelae such as increased reactive oxygen species in the heart, cardiomyocyte apoptosis, and direct induction of cardiac hypertrophy [34•].

What Happens with Weight Loss?

Weight loss ameliorates many of the comorbidities that are present in obesity: BP, diabetes/insulin resistance, obstructive sleep apnea, and dyslipidemia all improve. Sympathetic tone is also improved. Over time, these beneficial effects of weight loss lead to improvement in cardiac structure and function.

The most dramatic pediatric evidence we have for the favorable cardiac effects of weight loss comes from bariatric surgery studies. Ippisch et al. published pre–post results of 38 morbidly obese adolescents aged 13–19 years who underwent bariatric surgery [41]. After 10 months of follow-

up, mean weight loss was 59 kg [standard deviation (SD) 15 kg], mean change in BMI was -20 kg/m^2 (SD 5 kg/m^2), mean change in heart rate was -18 beats per minute (SD 20 bpm), mean change in systolic BP was -12 mmHg (SD 15 mmHg), and mean change in diastolic BP was -3 mmHg (SD 16 mmHg). Even more striking was the mean change in LVMI, which was $-12 \text{ g/m}^{2.7}$, with mean LVMI declining from $54 \text{ g/m}^{2.7}$ (SD $13 \text{ g/m}^{2.7}$) to $42 \text{ g/m}^{2.7}$ (SD $10 \text{ g/m}^{2.7}$), $p < 0.0001$.

This decrease in LVMI was independent of systolic and diastolic BP and was only predicted by degree of adiposity.

Is Weight Loss More Important than Lowering BP When Aiming to Achieve LVH Regression?

Evidence in children and adults points to the beneficial effects of BP lowering on cardiac geometry [42, 43]. As such, the pediatric hypertension guidelines clearly recommend starting or intensifying pharmacological anti-hypertensive therapy in children when LVH is present. However, as both hypertension and overweight/obesity have become more prevalent in the USA, it has become increasingly evident that each of these CVD risk factors has a role in the development of LVH and therefore presents a treatment target when aiming to achieve regression.

Adult trial data has led some to conclude that persistent obesity may inhibit our ability to reduce LVM despite good BP control and that hypertensive LVH may be sustained when weight loss is not achieved. Gerds et al. was able to show that despite comparable BP reduction, hypertensive obese individuals with LVH have a blunted response to therapy compared to normal weight patients [44]. Similarly, treated hypertensive adults who did not experience the anticipated decrease in LVM over time in the Strong Heart Study had similar BPs to those who did have the anticipated regression, but had greater measures of adiposity (BMI, waist/hip ratio) as well as higher heart rate and albuminuria. Multivariable regression confirmed baseline BMI to be an independent predictor of lack of LVM regression [45].

Pediatric data demonstrate a similar lack of LVH regression when only BP control is achieved. A study conducted in hypertensive European children reported that successful treatment of hypertension was not associated with LVH regression; instead, a decrease in waist circumference was the biggest predictor of LVMI decline [46]. Among a more racially diverse population of treated hypertensive American children followed for a year, measures of adiposity, not BP, were independently associated with change in LVMI over time. Children who were overweight or obese throughout the study had a greater increase in LVMI over time than those who were of healthy weight despite good BP control [mean change LVMI $6.4 \text{ g/m}^{2.7}$ (9.6 SD) vs $0.95 \text{ g/m}^{2.7}$ (8.9 SD); $p = 0.056$] [47].

One common theme is that overweight and obesity often cluster with hypertension in children and treatment of each has beneficial cardiac effects. However, the simultaneous presence of both obesity and hypertension may result in an amplified response by the heart, greater than would be seen with the presence of either alone. This potential additive and/or interactive effects of obesity and BP on cardiac structure and function has been described for several decades [48••]. In adults, BP has been shown to have a differential effect on LVMI based on the presence or absence of obesity: hypertension increased LVMI among adults with increased waist circumference, but not among those with a normal waist circumference [49]. The degree to which body mass and BP contribute to LVMI may also be on different orders of magnitude. Palatini et al. followed middle-aged adults for 20 years and found that an increase in BMI of 1 kg/m² led to a similar odds of developing abnormal LV geometry as a 10-mmHg increase in systolic BP [odds ratio (OR) 1.07, $p < 0.0001$ and OR 1.22, $p < 0.0001$] [50]. When examined longitudinally in a large biracial sample of adults, BP and BMI in childhood and adulthood were both associated with LVH and LVMI in adulthood, but BMI had a greater association with the cardiac outcomes [51].

Children also have evidence for an interactive effect of overweight/obesity and BP on the heart. In a single-center, case–control study of children 9–18 years of age with untreated incident primary hypertension, only measures of adiposity were associated with the presence of LVH in multivariable adjusted analysis. However, when the children were stratified into groups based on obesity and LVH status, non-obese children with LVH had significantly higher 24-h ambulatory systolic BP than did the non-obese children without LVH. In the obese children, 24-h ambulatory systolic BP was no different between those with and without LVH [52].

So, naturally this leads to the question—where should treatment efforts be focused? Again, guidelines state that hypertensive children with LVH should have antihypertensive medications initiated or increased to promote LVH regression. As reviewed above, this may not be enough when treating overweight or obese patients with LVH. One must not forget that common to all children with hypertension is the need for prescribed therapeutic lifestyle change [10••, 17•]. This heart healthy lifestyle is similar to that prescribed to overweight and obese children with essential tenets being weight loss when overweight, daily moderate to vigorous physical activity, avoidance of sugar-sweetened beverages, and a focus on dietary choices to include low-fat dairy, fruits and vegetables, and high-fiber foods. Recognizing how difficult it is for families to adhere to these recommendations and successfully achieve weight loss, either greater efforts need to be made to assist families with weight loss goals or lower BP targets should be sought for those with obesity, hypertension, and persistent LVH. More than anything, these findings speak to the need for

a paradigm shift in how we approach childhood overweight and obesity, focusing on prevention rather than treatment [53]. Decreasing the prevalence of CVD risk factors in childhood and adolescence will allow us to prevent adult CVD and the devastating sequelae that result.

Conclusions

Obesity remains highly prevalent among children and adolescents. Overweight and obese youth are at increased risk for hypertension, dyslipidemia, and insulin resistance/diabetes mellitus as well as end organ damage such as atherosclerosis and LVH. While traditionally thought to be a consequence of increased afterload in hypertensive individuals, LVH is now known to be independently associated with measures of adiposity. There are multiple hemodynamic and non-hemodynamic factors to explain the role of obesity on this pathological remodeling of the heart. Further, evidence suggests that the presence of both hypertension and obesity may have a greater effect on the heart than either CVD risk factor alone. With obesity a common cause of pediatric hypertension, particularly among adolescents, prevention of obesity and early treatment with weight loss remain of paramount importance as we work to decrease the CVD risk in children.

Acknowledgments None of the sponsors had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The first draft of this manuscript was written by Tammy M. Brady, and there was no honorarium, grant, or other form of payment given to anyone to produce the manuscript.

Compliance with Ethics Guidelines

Conflict of Interest Dr. Brady declares no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Funding Source TMB is funded by the NIH/NHLBI (1K23 HL119622-01).

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. *JAMA*. 2014;311:806–14.

2. Fixler DE, Laird WP, Fitzgerald V, Stead S, Adams R. Hypertension screening in schools: results of the Dallas study. *Pediatrics*. 1979;63:32–6.
3. Sinaiko AR, Gomez-Marin O, Prineas RJ. Prevalence of “significant” hypertension in junior high school-aged children: the Children and Adolescent Blood Pressure Program. *J Pediatr*. 1989;114:664–9.
4. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. *Pediatrics*. 2004;113:475–82.
5. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and pre-hypertension among adolescents. *J Pediatr*. 2007;150:640–4. 4 e1.
6. Maggio AB, Aggoun Y, Marchand LM, Martin XE, Herrmann F, Beghetti M, et al. Associations among obesity, blood pressure, and left ventricular mass. *J Pediatr*. 2008;152:489–93.
7. Friedemann C, Heneghan C, Mahtani K, Thompson M, Perera R, Ward AM. Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. *BMJ*. 2012;345:e4759.
8. Berenson GS, Srinivasan SR, Bao W, Newman 3rd WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. *N Engl J Med*. 1998;338:1650–6.
9. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol*. 1986;57:450–8.
10. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* 2004;114: 555–76. This describes the recommended evaluation and treatment approach for pediatric hypertension, including details regarding the role of echocardiography.
11. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. *J Am Soc Echocardiogr*. 2009;22:709–14. **This provides age- and sex-specific left ventricular mass index percentiles for children, which is necessary in the diagnosis of left ventricular hypertrophy.**
12. de Simone G, Daniels SR, Kimball TR, Roman MJ, Romano C, Chinali M, et al. Evaluation of concentric left ventricular geometry in humans: evidence for age-related systematic underestimation. *Hypertension*. 2005;45:64–8.
13. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartocchini C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. *J Am Coll Cardiol*. 1995;25:871–8.
14. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. *J Am Coll Cardiol*. 1995;25:1056–62.
15. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. *Circulation*. 2008;117:3171–80.
16. Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. *Pediatrics*. 2007;120:340–5.
17. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics* 2011;128 Suppl 5:S213–56. Most recent guidelines regarding cardiovascular disease risk factor screening, evaluation and treatment in children. Provides specific dietary recommendations for cardiovascular risk reduction.
18. Hanevold C, Waller J, Daniels S, Portman R, Sorof J. The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association. *Pediatrics*. 2004;113:328–33.
19. McNiece KL, Gupta-Malhotra M, Samuels J, Bell C, Garcia K, Poffenbarger T, et al. Left ventricular hypertrophy in hypertensive adolescents: analysis of risk by 2004 National High Blood Pressure Education Program Working Group staging criteria. *Hypertension*. 2007;50:392–5.
20. Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. *Pediatrics*. 2003;111:61–6.
21. Urbina EM, Khoury PR, McCoy C, Daniels SR, Kimball TR, Dolan LM. Cardiac and vascular consequences of pre-hypertension in youth. *J Clin Hypertens (Greenwich)*. 2011;13: 332–42.
22. Stabouli S, Kotsis V, Rizos Z, Toumanidis S, Karagianni C, Constantopoulos A, et al. Left ventricular mass in normotensive, prehypertensive and hypertensive children and adolescents. *Pediatr Nephrol*. 2009;24:1545–51.
23. Brady TM, Fivush B, Flynn JT, Parekh R. Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. *J Pediatr*. 2008;152:73–8. 8 e1.
24. Pruetz CS, Fivush BA, Flynn JT, Brady TM. Effects of obesity and race on left ventricular geometry in hypertensive children. *Pediatr Nephrol*. 2013;28:2015–22.
25. Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS. Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. *Circulation*. 1995;91:2400–6.
26. Crowley DI, Khoury PR, Urbina EM, Ippisch HM, Kimball TR. Cardiovascular impact of the pediatric obesity epidemic: higher left ventricular mass is related to higher body mass index. *J Pediatr*. 2011;158:709–14 e1.
27. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. *JAMA*. 1991;266:231–6.
28. Dusan P, Tamara I, Goran V, Gordana ML, Amira PA. Left ventricular mass and diastolic function in obese children and adolescents. *Pediatr Nephrol*. 2015;30:645–52.
29. Sivanandam S, Sinaiko AR, Jacobs Jr DR, Steffen L, Moran A, Steinberger J. Relation of increase in adiposity to increase in left ventricular mass from childhood to young adulthood. *Am J Cardiol*. 2006;98:411–5.
30. Li X, Li S, Ulusoy E, Chen W, Srinivasan SR, Berenson GS. Childhood adiposity as a predictor of cardiac mass in adulthood: the Bogalusa Heart Study. *Circulation*. 2004;110:3488–92.
31. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. *Physiol Rev*. 2008;88:389–419. **Excellent, comprehensive review of the pathogenesis and mechanisms of obesity-related cardiac remodeling.**
32. Messerli FH, Christie B, DeCarvalho JG, Aristimuno GG, Suarez DH, Dreslinski GR, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. *Arch Intern Med*. 1981;141: 81–5.
33. Bastien M, Poirier P, Lemieux I, Despres JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. *Prog Cardiovasc Dis*. 2014;56:369–81.
34. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol*. 2011;11:85–97. **Excellent review describing the role the dysfunctional adipocyte and various adipokines in cardiovascular disease and in the regulation of metabolic function.**

35. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. *BMJ*. 2000;320:479–82.
36. Cloward TV, Walker JM, Farney RJ, Anderson JL. Left ventricular hypertrophy is a common echocardiographic abnormality in severe obstructive sleep apnea and reverses with nasal continuous positive airway pressure. *Chest*. 2003;124:594–601.
37. •• Murdolo G, Angeli F, Reboldi G, Di Giacomo L, Aita A, Bartolini C, et al. Left ventricular hypertrophy and obesity: only a matter of fat? *High Blood Press Cardiovasc Prev*. 2015;22:29–41. **Excellent review describing the association of obesity with left ventricular hypertrophy, focusing on the role of the dysfunctional adipocyte, interstitial fat infiltration and the role of lipotoxicity.**
38. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. *Nat Clin Pract Cardiovasc Med*. 2005;2:536–43.
39. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. *Diabetes*. 2007;56:1198–209.
40. Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. *Hypertens Res*. 2012;35:4–16.
41. Ippisch HM, Inge TH, Daniels SR, Wang B, Khoury PR, Witt SA, et al. Reversibility of cardiac abnormalities in morbidly obese adolescents. *J Am Coll Cardiol*. 2008;51:1342–8.
42. Seeman T, Dostalek L, Gilik J. Control of hypertension in treated children and its association with target organ damage. *Am J Hypertens*. 2012;25:389–95.
43. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. *Hypertension*. 2009;54:1084–91.
44. Gerds E, de Simone G, Lund BP, Okin PM, Wachtell K, Boman K, et al. Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. *Nutr Metab Cardiovasc Dis*. 2013;23:122–9.
45. de Simone G, Devereux RB, Izzo R, Girfoglio D, Lee ET, Howard BV, et al. Lack of reduction of left ventricular mass in treated hypertension: the strong heart study. *J Am Heart Assoc*. 2013;2:e000144.
46. Litwin M, Niemirska A, Sladowska-Kozłowska J, Wierzbicka A, Janas R, Wawer ZT, et al. Regression of target organ damage in children and adolescents with primary hypertension. *Pediatr Nephrol*. 2010;25:2489–99.
47. Brady TM, Appel LJ, Holmes KW, Fivush B, Miller ER, 3rd. Association between adiposity and left ventricular mass in children with hypertension. *J Clin Hypertens (Greenwich)*.
48. •• Lavie CJ, Messerli FH. Cardiovascular adaptation to obesity and hypertension. *Chest*. 1986;90:275–9. **Excellent review of the independent and combined effects of obesity and blood pressure on the cardiovascular system.**
49. Norton GR, Majane OH, Libhaber E, Maseko MJ, Makaula S, Libhaber C, et al. The relationship between blood pressure and left ventricular mass index depends on an excess adiposity. *J Hypertens*. 2009;27:1873–83.
50. Palatini P, Saladini F, Mos L, Benetti E, Bortolazzi A, Cozzio S, et al. Obesity is a strong determinant of hypertensive target organ damage in young-to-middle-age patients. *Int J Obes (Lond)*. 2013;37:224–9.
51. Lai CC, Sun D, Cen R, Wang J, Li S, Fernandez-Alonso C, et al. Impact of long-term burden of excessive adiposity and elevated blood pressure from childhood on adulthood left ventricular remodeling patterns: the Bogalusa Heart Study. *J Am Coll Cardiol*. 2014;64:1580–7.
52. Gupta-Malhotra M, Hashmi SS, Poffenbarger T, McNiece-Redwine K. Left ventricular hypertrophy phenotype in childhood-onset essential hypertension. *J Clin Hypertens (Greenwich)*.
53. Daniels SR, Hassink SG. The role of the pediatrician in primary prevention of obesity. *Pediatrics*. 2015;136:e275–92.